Neuroendocrine tumor (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Neuroendocrine tumor" in English language version.

refsWebsite

Global rank English rank

95nih.gov

4^th place

64doi.org

2^nd place

23semanticscholar.org

11^th place

8^th place

16web.archive.org

1^st place

4cancer.gov

1,684^th place

1,350^th place

2omim.org

4,380^th place

4,305^th place

2carcinoid.org

low place

2medicinenet.com

3,840^th place

3,358^th place

2handle.net

102^nd place

76^th place

1uptodate.com

3,771^st place

2,605^th place

1healthcommunities.com

low place

1cancernetwork.com

low place

1lecturio.com

5,619^th place

2,948^th place

1bbc.co.uk

8^th place

10^th place

1time.com

61^st place

54^th place

1harvard.edu

18^th place

17^th place

1gpnotebook.co.uk

low place

1discoverymedicine.com

low place

1medscape.com

719^th place

636^th place

1nccn.org

low place

1mosaicscience.com

low place

1icancer.org.uk

low place

1telegraph.co.uk

30^th place

24^th place

bbc.co.uk

news.bbc.co.uk

Kinver M (January 1, 2010). "Tasmanian devil facial cancer origins 'identified'". BBC. Archived from the original on January 2, 2010.

cancer.gov

"Islet Cell Tumors (Endocrine Pancreas)". National Cancer Institute. Archived from the original on 2011-06-07.
"Gastrointestinal Carcinoid Tumors Treatment". National Cancer Institute. Archived from the original on 2011-06-27.
"Merkel cell tumors". National Cancer Institute. 21 February 2006. Archived from the original on 2011-06-07.
"Pheochromocytoma and Paraganglioma". National Cancer Institute. Archived from the original on 2011-06-07.

cancernetwork.com

Benson AB, Myerson RJ, Sasson AR (March 2011). "Pancreatic, neuroendocrine GI, and adrenal cancers.". Cancer Management: A Multidisciplinary Approach (13th ed.). UBM Medica. ISBN 978-0-615-41824-7. Archived from the original on 2011-05-15., cancernetwork.com; accessed November 8, 2015.

carcinoid.org

Pommier R (October 2003). The role of surgery and chemoembolization in the management of carcinoid. California Carcinoid Fighters Conference. Archived from the original on 2015-09-15.
Kvols LK (2002). "Carcinoid Tumors and the Carcinoid Syndrome: What's New in the Therapeutic Pipeline". Carcinoid Symposium 2002. The Carcinoid Cancer Foundation. Archived from the original on 2015-01-05.

discoverymedicine.com

Hofman MS, Hicks RJ (July 2012). "Changing paradigms with molecular imaging of neuroendocrine tumors". Discovery Medicine. 14 (74): 71–81. PMID 22846204. Retrieved November 8, 2015.

doi.org

Ramage JK, Davies AH, Ardill J, Bax N, Caplin M, Grossman A, et al. (June 2005). "Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours". Gut. 54. 54 (Suppl 4): iv1 – i16. doi:10.1136/gut.2004.053314. PMC 1867801. PMID 15888809.
Scalettar BA, Jacobs C, Fulwiler A, Prahl L, Simon A, Hilken L, Lochner JE (September 2012). "Hindered submicron mobility and long-term storage of presynaptic dense-core granules revealed by single-particle tracking". Developmental Neurobiology. 72 (9): 1181–1195. doi:10.1002/dneu.20984. PMC 3512567. PMID 21976424.
Oronsky B, Ma PC, Morgensztern D, Carter CA (December 2017). "Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas". Neoplasia. 19 (12): 991–1002. doi:10.1016/j.neo.2017.09.002. PMC 5678742. PMID 29091800.
Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S (August 2010). "The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems". Pancreas. 39 (6): 707–712. doi:10.1097/MPA.0b013e3181ec124e. PMID 20664470. S2CID 3735444.
Tan EH, Tan CH (January 2011). "Imaging of gastroenteropancreatic neuroendocrine tumors". World Journal of Clinical Oncology. 2 (1): 28–43. doi:10.5306/wjco.v2.i1.28. PMC 3095463. PMID 21603312.
van Eeden S, Offerhaus GJ, Hart AA, Boerrigter L, Nederlof PM, Porter E, van Velthuysen ML (December 2007). "Goblet cell carcinoid of the appendix: a specific type of carcinoma". Histopathology. 51 (6): 763–773. doi:10.1111/j.1365-2559.2007.02883.x. PMID 18042066. S2CID 20185589.
Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens LA, et al. (March 2022). "Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms". Endocrine Pathology. 33 (1): 115–154. doi:10.1007/s12022-022-09708-2. PMID 35294740. S2CID 247455289.
Liu Y, Sturgis CD, Grzybicki DM, Jasnosz KM, Olson PR, Tong M, et al. (September 2001). "Microtubule-associated protein-2: a new sensitive and specific marker for pulmonary carcinoid tumor and small cell carcinoma". Modern Pathology. 14 (9): 880–885. doi:10.1038/modpathol.3880406. PMID 11557784. S2CID 24740130.
Rufini V, Calcagni ML, Baum RP (July 2006). "Imaging of neuroendocrine tumors". Seminars in Nuclear Medicine. 36 (3): 228–247. doi:10.1053/j.semnuclmed.2006.03.007. PMID 16762613.
Oberg K, Jelic S (May 2008). "Neuroendocrine bronchial and thymic tumors: ESMO clinical recommendation for diagnosis, treatment and follow-up". Annals of Oncology. 19 (Suppl 2): ii102 – ii103. doi:10.1093/annonc/mdn116. PMID 18456740.
Beasley MB, Brambilla E, Travis WD (April 2005). "The 2004 World Health Organization classification of lung tumors". Seminars in Roentgenology. 40 (2): 90–97. doi:10.1053/j.ro.2005.01.001. PMID 15898407.
Gustafsson BI, Kidd M, Chan A, Malfertheiner MV, Modlin IM (July 2008). "Bronchopulmonary neuroendocrine tumors". Cancer. 113 (1): 5–21. doi:10.1002/cncr.23542. PMID 18473355. S2CID 22143641.
Wick MR, Berg LC, Hertz MI (June 1992). "Large cell carcinoma of the lung with neuroendocrine differentiation. A comparison with large cell "undifferentiated" pulmonary tumors". American Journal of Clinical Pathology. 97 (6): 796–805. doi:10.1093/ajcp/97.6.796. PMID 1317668.
Massironi S, Sciola V, Peracchi M, Ciafardini C, Spampatti MP, Conte D (September 2008). "Neuroendocrine tumors of the gastro-entero-pancreatic system". World Journal of Gastroenterology. 14 (35): 5377–5384. doi:10.3748/wjg.14.5377. PMC 2744160. PMID 18803349.
Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, et al. (January 2008). "Gastroenteropancreatic neuroendocrine tumours". The Lancet. Oncology. 9 (1): 61–72. doi:10.1016/S1470-2045(07)70410-2. PMID 18177818. S2CID 46127116.
Metz DC, Jensen RT (November 2008). "Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors". Gastroenterology. 135 (5): 1469–1492. doi:10.1053/j.gastro.2008.05.047. PMC 2612755. PMID 18703061.
Griniatsos J, Michail O (April 2010). "Appendiceal neuroendocrine tumors: Recent insights and clinical implications". World Journal of Gastrointestinal Oncology. 2 (4): 192–196. doi:10.4251/wjgo.v2.i4.192. PMC 2999180. PMID 21160597.
Ni SJ, Sheng WQ, Du X (April 2010). "Pathologic research update of colorectal neuroendocrine tumors". World Journal of Gastroenterology. 16 (14): 1713–1719. doi:10.3748/wjg.v16.i14.1713. PMC 2852818. PMID 20380002.
Konishi T, Watanabe T, Nagawa H, Oya M, Ueno M, Kuroyanagi H, et al. (May 2010). "Treatment of colorectal carcinoids: A new paradigm". World Journal of Gastrointestinal Surgery. 2 (5): 153–156. doi:10.4240/wjgs.v2.i5.153. PMC 2999232. PMID 21160865.
Nikfarjam M, Muralidharan V, Christophi C (2004). "Primary hepatic carcinoid tumours". HPB. 6 (1): 13–17. doi:10.1080/13651820310017228. PMC 2020649. PMID 18333038.
Moriura S, Ikeda S, Hirai M, Naiki K, Fujioka T, Yokochi K, Gotou S (September 1993). "Hepatic gastrinoma". Cancer. 72 (5): 1547–1550. doi:10.1002/1097-0142(19930901)72:5<1547::AID-CNCR2820720510>3.0.CO;2-C. PMID 8348490.
Murali R, Kneale K, Lalak N, Delprado W (November 2006). "Carcinoid tumors of the urinary tract and prostate". Archives of Pathology & Laboratory Medicine. 130 (11): 1693–1706. doi:10.5858/2006-130-1693-CTOTUT. PMID 17076534.
Usmani S, Orevi M, Stefanelli A, Zaniboni A, Gofrit ON, Bnà C, et al. (June 2019). "Neuroendocrine differentiation in castration resistant prostate cancer. Nuclear medicine radiopharmaceuticals and imaging techniques: A narrative review". Critical Reviews in Oncology/Hematology. 138: 29–37. doi:10.1016/j.critrevonc.2019.03.005. PMID 31092382. S2CID 131934021.
Davies AH, Beltran H, Zoubeidi A (May 2018). "Cellular plasticity and the neuroendocrine phenotype in prostate cancer". Nature Reviews. Urology. 15 (5): 271–286. doi:10.1038/nrurol.2018.22. PMID 29460922. S2CID 4732323.
Jensen RT, Berna MJ, Bingham DB, Norton JA (October 2008). "Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies". Cancer. 113 (7 Suppl): 1807–1843. doi:10.1002/cncr.23648. PMC 2574000. PMID 18798544.
Hirsch NP, Murphy A, Radcliffe JJ (April 2001). "Neurofibromatosis: clinical presentations and anaesthetic implications". British Journal of Anaesthesia. 86 (4): 555–564. doi:10.1093/bja/86.4.555. PMID 11573632.
Lodish MB, Stratakis CA (June 2010). "Endocrine tumours in neurofibromatosis type 1, tuberous sclerosis and related syndromes". Best Practice & Research. Clinical Endocrinology & Metabolism. 24 (3): 439–449. doi:10.1016/j.beem.2010.02.002. PMC 2939061. PMID 20833335.
Dworakowska D, Grossman AB (March 2009). "Are neuroendocrine tumours a feature of tuberous sclerosis? A systematic review". Endocrine-Related Cancer. 16 (1): 45–58. doi:10.1677/ERC-08-0142. PMID 18978035.
Basturk O, Yang Z, Tang LH, Hruban RH, Adsay V, McCall CM, et al. (May 2015). "The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms". The American Journal of Surgical Pathology. 39 (5): 683–690. doi:10.1097/PAS.0000000000000408. PMC 4398606. PMID 25723112.
Kimura W, Kuroda A, Morioka Y (July 1991). "Clinical pathology of endocrine tumors of the pancreas. Analysis of autopsy cases". Digestive Diseases and Sciences. 36 (7): 933–942. doi:10.1007/BF01297144. PMID 2070707. S2CID 20567425. "[In] 800 autopsy cases, ... incidence of tumor was 10% (6/60) in individuals having histiological studies of all sections of the pancreas"
Burns WR, Edil BH (March 2012). "Neuroendocrine pancreatic tumors: guidelines for management and update". Current Treatment Options in Oncology. 13 (1): 24–34. doi:10.1007/s11864-011-0172-2. PMID 22198808. S2CID 7329783.
Bostanci A (February 2005). "Wildlife biology. A devil of a disease". Science. 307 (5712): 1035. doi:10.1126/science.307.5712.1035. PMID 15718445. S2CID 54100368. The tumors [of Devil facial tumor disease] have been characterized as a neuroendocrine cancer
Langley K (September 1994). "The neuroendocrine concept today". Annals of the New York Academy of Sciences. 733 (1): 1–17. Bibcode:1994NYASA.733....1L. doi:10.1111/j.1749-6632.1994.tb17251.x. PMID 7978856. S2CID 33139633.
Ferolla P, Faggiano A, Mansueto G, Avenia N, Cantelmi MG, Giovenali P, et al. (March 2008). "The biological characterization of neuroendocrine tumors: the role of neuroendocrine markers". Journal of Endocrinological Investigation. 31 (3): 277–286. doi:10.1007/bf03345602. PMID 18401212. S2CID 25108086.
Oberg K (July 2005). "Neuroendocrine tumors of the gastrointestinal tract: recent advances in molecular genetics, diagnosis, and treatment". Current Opinion in Oncology. 17 (4): 386–391. doi:10.1097/01.cco.0000167739.56948.a9. PMID 15933475. S2CID 208286399.
van Essen M, Sundin A, Krenning EP, Kwekkeboom DJ (February 2014). "Neuroendocrine tumours: the role of imaging for diagnosis and therapy". Nature Reviews. Endocrinology. 10 (2): 102–114. doi:10.1038/nrendo.2013.246. PMID 24322649. S2CID 40129404.
Hofman MS, Kong G, Neels OC, Eu P, Hong E, Hicks RJ (February 2012). "High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours". Journal of Medical Imaging and Radiation Oncology. 56 (1): 40–47. doi:10.1111/j.1754-9485.2011.02327.x. PMID 22339744. S2CID 21843609.
Scott AT, Howe JR (August 2018). "Management of Small Bowel Neuroendocrine Tumors". Journal of Oncology Practice. 14 (8): 471–482. doi:10.1200/JOP.18.00135. PMC 6091496. PMID 30096273.
Hofland J, Kaltsas G, de Herder WW (April 2020). "Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms". Endocrine Reviews. 41 (2): 371–403. doi:10.1210/endrev/bnz004. PMC 7080342. PMID 31555796.
Nilica B, Waitz D, Stevanovic V, Uprimny C, Kendler D, Buxbaum S, et al. (August 2016). "Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle". European Journal of Nuclear Medicine and Molecular Imaging. 43 (9): 1585–1592. doi:10.1007/s00259-016-3328-2. PMC 4932132. PMID 26922350.
Van Buren G, Rashid A, Yang AD, Abdalla EK, Gray MJ, Liu W, et al. (August 2007). "The development and characterization of a human midgut carcinoid cell line". Clinical Cancer Research. 13 (16): 4704–4712. doi:10.1158/1078-0432.CCR-06-2723. PMID 17699847.
Berretta M, Cappellani A, Di Vita M, Berretta S, Nasti G, Bearz A, et al. (January 2010). "Biomarkers in neuroendocrine tumors". Frontiers in Bioscience. 2 (1): 332–342. doi:10.2741/s68. PMID 20036951.
Mukhopadhyay S, Dermawan JK, Lanigan CP, Farver CF (January 2019). "Insulinoma-associated protein 1 (INSM1) is a sensitive and highly specific marker of neuroendocrine differentiation in primary lung neoplasms: an immunohistochemical study of 345 cases, including 292 whole-tissue sections". Modern Pathology. 32 (1): 100–109. doi:10.1038/s41379-018-0122-7. PMID 30154579. S2CID 52110673.
Warner RR (May 2005). "Enteroendocrine tumors other than carcinoid: a review of clinically significant advances". Gastroenterology. 128 (6): 1668–1684. doi:10.1053/j.gastro.2005.03.078. PMID 15887158.
Öberg K (1998). "Carcinoid Tumors: Current Concepts in Diagnosis and Treatment". The Oncologist. 3 (5): 339–345. doi:10.1634/theoncologist.3-5-339. PMID 10388123.
Oberg K, Akerström G, Rindi G, Jelic S (May 2010). "Neuroendocrine gastroenteropancreatic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up". Annals of Oncology. 21 (Suppl 5): v223 – v227. doi:10.1093/annonc/mdq192. PMID 20555086.
Clark OH, Benson AB, Berlin JD, Choti MA, Doherty GM, Engstrom PF, et al. (July 2009). "NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors". Journal of the National Comprehensive Cancer Network. 7 (7): 712–747. doi:10.6004/jnccn.2009.0050. PMID 19635226.
Rinke A, Auernhammer CJ, Bodei L, Kidd M, Krug S, Lawlor R, et al. (September 2021). "Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine?". Gut. 70 (9): 1768–1781. doi:10.1136/gutjnl-2020-321300. PMID 33692095. S2CID 232172557.
Oberg K, Kvols L, Caplin M, Delle Fave G, de Herder W, Rindi G, et al. (June 2004). "Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system". Annals of Oncology. 15 (6): 966–973. doi:10.1093/annonc/mdh216. PMID 15151956.
Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. (October 2009). "Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group". Journal of Clinical Oncology. 27 (28): 4656–4663. doi:10.1200/JCO.2009.22.8510. PMID 19704057.
Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, et al. (July 2014). "Lanreotide in metastatic enteropancreatic neuroendocrine tumors". The New England Journal of Medicine. 371 (3): 224–233. doi:10.1056/NEJMoa1316158. PMID 25014687.
Chan JA, Kulke MH (May 2009). "Progress in the treatment of neuroendocrine tumors". Current Oncology Reports. 11 (3): 193–199. doi:10.1007/s11912-009-0028-0. PMC 4029419. PMID 19336011.
Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. (January 2017). "Phase 3 Trial of ¹⁷⁷Lu-Dotatate for Midgut Neuroendocrine Tumors". The New England Journal of Medicine. 376 (2): 125–135. doi:10.1056/nejmoa1607427. hdl:2445/125256. PMC 5895095. PMID 28076709.
Kratochwil C, Giesel FL, Bruchertseifer F, Mier W, Apostolidis C, Boll R, et al. (November 2014). "²¹³Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience". European Journal of Nuclear Medicine and Molecular Imaging. 41 (11): 2106–2119. doi:10.1007/s00259-014-2857-9. PMC 4525192. PMID 25070685.
Kashyap R, Hofman MS, Michael M, Kong G, Akhurst T, Eu P, et al. (February 2015). "Favourable outcomes of (177)Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours". European Journal of Nuclear Medicine and Molecular Imaging. 42 (2): 176–185. doi:10.1007/s00259-014-2906-4. PMID 25209134. S2CID 20740102.
Hofman MS, Michael M, Kashyap R, Hicks RJ (June 2015). "Modifying the Poor Prognosis Associated with 18F-FDG-Avid NET with Peptide Receptor Chemo-Radionuclide Therapy (PRCRT)". Journal of Nuclear Medicine. 56 (6): 968–969. doi:10.2967/jnumed.115.154500. PMID 25814516. S2CID 207407820.
Welsh JS, Kennedy AS, Thomadsen B (2006). "Selective Internal Radiation Therapy (SIRT) for liver metastases secondary to colorectal adenocarcinoma". International Journal of Radiation Oncology, Biology, Physics. 66 (2 Suppl): S62 – S73. doi:10.1016/j.ijrobp.2005.09.011. PMID 16979443.
Salem R, Thurston KG, Carr BI, Goin JE, Geschwind JF (September 2002). "Yttrium-90 microspheres: radiation therapy for unresectable liver cancer". Journal of Vascular and Interventional Radiology. 13 (9 Pt 2): S223 – S229. doi:10.1016/S1051-0443(07)61790-4. PMID 12354840.
Detjen K, Hammerich L, Özdirik B, Demir M, Wiedenmann B, Tacke F, et al. (2020-07-02). "Models of Gastroenteropancreatic Neuroendocrine Neoplasms: Current Status and Future Directions". Neuroendocrinology. 111 (3): 217–236. doi:10.1159/000509864. PMID 32615560.
April-Monn SL, Kirchner P, Detjen K, Bräutigam K, Trippel MA, Grob T, et al. (March 2024). "Patient derived tumoroids of high grade neuroendocrine neoplasms for more personalized therapies". npj Precision Oncology. 8 (1): 59. doi:10.1038/s41698-024-00549-2. PMC 10907580. PMID 38429350.
April-Monn SL, Wiedmer T, Skowronska M, Maire R, Schiavo Lena M, Trippel M, et al. (2020-04-03). "Three-Dimensional Primary Cell Culture: A Novel Preclinical Model for Pancreatic Neuroendocrine Tumors". Neuroendocrinology. 111 (3): 273–287. doi:10.1159/000507669. hdl:11392/2447420. PMID 32241015. S2CID 214768622.
Oberg K, Castellano D (March 2011). "Current knowledge on diagnosis and staging of neuroendocrine tumors". Cancer and Metastasis Reviews. 30 (Suppl 1): 3–7. doi:10.1007/s10555-011-9292-1. PMID 21311954. S2CID 29720754.
Kimura W, Kuroda A, Morioka Y (July 1991). "Clinical pathology of endocrine tumors of the pancreas. Analysis of autopsy cases". Digestive Diseases and Sciences. 36 (7): 933–942. doi:10.1007/BF01297144. PMID 2070707. S2CID 20567425.
Modlin IM, Shapiro MD, Kidd M (December 2004). "Siegfried Oberndorfer: origins and perspectives of carcinoid tumors". Human Pathology. 35 (12): 1440–1451. doi:10.1016/j.humpath.2004.09.018. PMID 15619202.

gpnotebook.co.uk

McMorran J, Crowther DC, McMorran S, Prince C, YoungMin S, Pleat J, Wacogne I. "investigations – General Practice Notebook". www.gpnotebook.co.uk. Archived from the original on 24 February 2017. Retrieved 23 February 2017.

handle.net

hdl.handle.net

Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. (January 2017). "Phase 3 Trial of ¹⁷⁷Lu-Dotatate for Midgut Neuroendocrine Tumors". The New England Journal of Medicine. 376 (2): 125–135. doi:10.1056/nejmoa1607427. hdl:2445/125256. PMC 5895095. PMID 28076709.
April-Monn SL, Wiedmer T, Skowronska M, Maire R, Schiavo Lena M, Trippel M, et al. (2020-04-03). "Three-Dimensional Primary Cell Culture: A Novel Preclinical Model for Pancreatic Neuroendocrine Tumors". Neuroendocrinology. 111 (3): 273–287. doi:10.1159/000507669. hdl:11392/2447420. PMID 32241015. S2CID 214768622.

harvard.edu

ui.adsabs.harvard.edu

Langley K (September 1994). "The neuroendocrine concept today". Annals of the New York Academy of Sciences. 733 (1): 1–17. Bibcode:1994NYASA.733....1L. doi:10.1111/j.1749-6632.1994.tb17251.x. PMID 7978856. S2CID 33139633.

healthcommunities.com

"Carcinoid Tumor Overview". Health Communities. Archived from the original on 2012-03-03.

icancer.org.uk

"iCancer web site". icancer.org.uk. Archived from the original on 2016-07-14. Retrieved 2016-07-03.

lecturio.com

"Cushing's Syndrome". The Lecturio Medical Concept Library. Retrieved 28 September 2021.

medicinenet.com

"Definition of Mesentery". MedicineNet. Retrieved 2018-04-21.
Fong T, Schoenfield LJ. "Arterial Chemotherapy Infusion of the Liver (and) Chemoembolization of the Liver (TACE)". medicinenet.com. Archived from the original on 2014-12-24. Retrieved 8 November 2015.

medscape.com

emedicine.medscape.com

Tebbi CK, Windle ML, Cripe TP, Sakamoto KM (1 April 2014). Coppes MJ (ed.). "Carcinoid Tumor". Medscape.com. WebMD LLC. Archived from the original on 15 December 2014. Retrieved 3 September 2014.

mosaicscience.com

Masters A (2014-10-14). "A plutocratic proposal". Mosaic. The Wellcome Trust. Archived from the original on 2016-05-29. Retrieved 2016-07-03.

nccn.org

"Neuroendocrine tumors, NCCN Guidelines Version 1.2015" (PDF). NCCN Guidelines. National Comprehensive Cancer Network, Inc. November 11, 2014. Retrieved December 25, 2014.

nih.gov

pubmed.ncbi.nlm.nih.gov

Ramage JK, Davies AH, Ardill J, Bax N, Caplin M, Grossman A, et al. (June 2005). "Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours". Gut. 54. 54 (Suppl 4): iv1 – i16. doi:10.1136/gut.2004.053314. PMC 1867801. PMID 15888809.
Scalettar BA, Jacobs C, Fulwiler A, Prahl L, Simon A, Hilken L, Lochner JE (September 2012). "Hindered submicron mobility and long-term storage of presynaptic dense-core granules revealed by single-particle tracking". Developmental Neurobiology. 72 (9): 1181–1195. doi:10.1002/dneu.20984. PMC 3512567. PMID 21976424.
Oronsky B, Ma PC, Morgensztern D, Carter CA (December 2017). "Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas". Neoplasia. 19 (12): 991–1002. doi:10.1016/j.neo.2017.09.002. PMC 5678742. PMID 29091800.
Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S (August 2010). "The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems". Pancreas. 39 (6): 707–712. doi:10.1097/MPA.0b013e3181ec124e. PMID 20664470. S2CID 3735444.
Tan EH, Tan CH (January 2011). "Imaging of gastroenteropancreatic neuroendocrine tumors". World Journal of Clinical Oncology. 2 (1): 28–43. doi:10.5306/wjco.v2.i1.28. PMC 3095463. PMID 21603312.
van Eeden S, Offerhaus GJ, Hart AA, Boerrigter L, Nederlof PM, Porter E, van Velthuysen ML (December 2007). "Goblet cell carcinoid of the appendix: a specific type of carcinoma". Histopathology. 51 (6): 763–773. doi:10.1111/j.1365-2559.2007.02883.x. PMID 18042066. S2CID 20185589.
Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens LA, et al. (March 2022). "Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms". Endocrine Pathology. 33 (1): 115–154. doi:10.1007/s12022-022-09708-2. PMID 35294740. S2CID 247455289.
Liu Y, Sturgis CD, Grzybicki DM, Jasnosz KM, Olson PR, Tong M, et al. (September 2001). "Microtubule-associated protein-2: a new sensitive and specific marker for pulmonary carcinoid tumor and small cell carcinoma". Modern Pathology. 14 (9): 880–885. doi:10.1038/modpathol.3880406. PMID 11557784. S2CID 24740130.
Rufini V, Calcagni ML, Baum RP (July 2006). "Imaging of neuroendocrine tumors". Seminars in Nuclear Medicine. 36 (3): 228–247. doi:10.1053/j.semnuclmed.2006.03.007. PMID 16762613.
Soga J (December 2003). "Carcinoids and their variant endocrinomas. An analysis of 11842 reported cases". Journal of Experimental & Clinical Cancer Research. 22 (4): 517–530. PMID 15053292.
Soga J, Yakuwa Y, Osaka M (October 1999). "Evaluation of 342 cases of mediastinal/thymic carcinoids collected from literature: a comparative study between typical carcinoids and atypical varieties". Annals of Thoracic and Cardiovascular Surgery. 5 (5): 285–292. PMID 10550713.
Oberg K, Jelic S (May 2008). "Neuroendocrine bronchial and thymic tumors: ESMO clinical recommendation for diagnosis, treatment and follow-up". Annals of Oncology. 19 (Suppl 2): ii102 – ii103. doi:10.1093/annonc/mdn116. PMID 18456740.
Beasley MB, Brambilla E, Travis WD (April 2005). "The 2004 World Health Organization classification of lung tumors". Seminars in Roentgenology. 40 (2): 90–97. doi:10.1053/j.ro.2005.01.001. PMID 15898407.
Gustafsson BI, Kidd M, Chan A, Malfertheiner MV, Modlin IM (July 2008). "Bronchopulmonary neuroendocrine tumors". Cancer. 113 (1): 5–21. doi:10.1002/cncr.23542. PMID 18473355. S2CID 22143641.
Wick MR, Berg LC, Hertz MI (June 1992). "Large cell carcinoma of the lung with neuroendocrine differentiation. A comparison with large cell "undifferentiated" pulmonary tumors". American Journal of Clinical Pathology. 97 (6): 796–805. doi:10.1093/ajcp/97.6.796. PMID 1317668.
Massironi S, Sciola V, Peracchi M, Ciafardini C, Spampatti MP, Conte D (September 2008). "Neuroendocrine tumors of the gastro-entero-pancreatic system". World Journal of Gastroenterology. 14 (35): 5377–5384. doi:10.3748/wjg.14.5377. PMC 2744160. PMID 18803349.
Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, et al. (January 2008). "Gastroenteropancreatic neuroendocrine tumours". The Lancet. Oncology. 9 (1): 61–72. doi:10.1016/S1470-2045(07)70410-2. PMID 18177818. S2CID 46127116.
Metz DC, Jensen RT (November 2008). "Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors". Gastroenterology. 135 (5): 1469–1492. doi:10.1053/j.gastro.2008.05.047. PMC 2612755. PMID 18703061.
Griniatsos J, Michail O (April 2010). "Appendiceal neuroendocrine tumors: Recent insights and clinical implications". World Journal of Gastrointestinal Oncology. 2 (4): 192–196. doi:10.4251/wjgo.v2.i4.192. PMC 2999180. PMID 21160597.
Ni SJ, Sheng WQ, Du X (April 2010). "Pathologic research update of colorectal neuroendocrine tumors". World Journal of Gastroenterology. 16 (14): 1713–1719. doi:10.3748/wjg.v16.i14.1713. PMC 2852818. PMID 20380002.
Konishi T, Watanabe T, Nagawa H, Oya M, Ueno M, Kuroyanagi H, et al. (May 2010). "Treatment of colorectal carcinoids: A new paradigm". World Journal of Gastrointestinal Surgery. 2 (5): 153–156. doi:10.4240/wjgs.v2.i5.153. PMC 2999232. PMID 21160865.
Soga J (December 2002). "Primary hepatic endocrinomas (carcinoids and variant neoplasms). A statistical evaluation of 126 reported cases". Journal of Experimental & Clinical Cancer Research. 21 (4): 457–468. PMID 12636090.
Nikfarjam M, Muralidharan V, Christophi C (2004). "Primary hepatic carcinoid tumours". HPB. 6 (1): 13–17. doi:10.1080/13651820310017228. PMC 2020649. PMID 18333038.
Moriura S, Ikeda S, Hirai M, Naiki K, Fujioka T, Yokochi K, Gotou S (September 1993). "Hepatic gastrinoma". Cancer. 72 (5): 1547–1550. doi:10.1002/1097-0142(19930901)72:5<1547::AID-CNCR2820720510>3.0.CO;2-C. PMID 8348490.
Soga J (March 2003). "Primary endocrinomas (carcinoids and variant neoplasms) of the gallbladder. A statistical evaluation of 138 reported cases". Journal of Experimental & Clinical Cancer Research. 22 (1): 5–15. PMID 12725316.
Soga J, Osaka M, Yakuwa Y (2001). "Gut-endocrinomas (carcinoids and related endocrine variants) of the breast: an analysis of 310 reported cases". International Surgery. 86 (1): 26–32. PMID 11890336.
Murali R, Kneale K, Lalak N, Delprado W (November 2006). "Carcinoid tumors of the urinary tract and prostate". Archives of Pathology & Laboratory Medicine. 130 (11): 1693–1706. doi:10.5858/2006-130-1693-CTOTUT. PMID 17076534.
Mikuz G (1993). "[Non-urothelial tumors of the urinary tract]". Verhandlungen der Deutschen Gesellschaft für Pathologie. 77: 180–198. PMID 7511278.
Soga J, Osaka M, Yakuwa Y (September 2001). "Gut-endocrinomas (carcinoids and related endocrine variants) of the uterine cervix: an analysis of 205 reported cases". Journal of Experimental & Clinical Cancer Research. 20 (3): 327–334. PMID 11718210.
Usmani S, Orevi M, Stefanelli A, Zaniboni A, Gofrit ON, Bnà C, et al. (June 2019). "Neuroendocrine differentiation in castration resistant prostate cancer. Nuclear medicine radiopharmaceuticals and imaging techniques: A narrative review". Critical Reviews in Oncology/Hematology. 138: 29–37. doi:10.1016/j.critrevonc.2019.03.005. PMID 31092382. S2CID 131934021.
Davies AH, Beltran H, Zoubeidi A (May 2018). "Cellular plasticity and the neuroendocrine phenotype in prostate cancer". Nature Reviews. Urology. 15 (5): 271–286. doi:10.1038/nrurol.2018.22. PMID 29460922. S2CID 4732323.
Jensen RT, Berna MJ, Bingham DB, Norton JA (October 2008). "Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies". Cancer. 113 (7 Suppl): 1807–1843. doi:10.1002/cncr.23648. PMC 2574000. PMID 18798544.
Hirsch NP, Murphy A, Radcliffe JJ (April 2001). "Neurofibromatosis: clinical presentations and anaesthetic implications". British Journal of Anaesthesia. 86 (4): 555–564. doi:10.1093/bja/86.4.555. PMID 11573632.
Lodish MB, Stratakis CA (June 2010). "Endocrine tumours in neurofibromatosis type 1, tuberous sclerosis and related syndromes". Best Practice & Research. Clinical Endocrinology & Metabolism. 24 (3): 439–449. doi:10.1016/j.beem.2010.02.002. PMC 2939061. PMID 20833335.
Dworakowska D, Grossman AB (March 2009). "Are neuroendocrine tumours a feature of tuberous sclerosis? A systematic review". Endocrine-Related Cancer. 16 (1): 45–58. doi:10.1677/ERC-08-0142. PMID 18978035.
Basturk O, Yang Z, Tang LH, Hruban RH, Adsay V, McCall CM, et al. (May 2015). "The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms". The American Journal of Surgical Pathology. 39 (5): 683–690. doi:10.1097/PAS.0000000000000408. PMC 4398606. PMID 25723112.
Kimura W, Kuroda A, Morioka Y (July 1991). "Clinical pathology of endocrine tumors of the pancreas. Analysis of autopsy cases". Digestive Diseases and Sciences. 36 (7): 933–942. doi:10.1007/BF01297144. PMID 2070707. S2CID 20567425. "[In] 800 autopsy cases, ... incidence of tumor was 10% (6/60) in individuals having histiological studies of all sections of the pancreas"
PDQ Adult Treatment Editorial Board (August 2022). "Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®): Health Professional Version". PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute. PMID 26389309.
Burns WR, Edil BH (March 2012). "Neuroendocrine pancreatic tumors: guidelines for management and update". Current Treatment Options in Oncology. 13 (1): 24–34. doi:10.1007/s11864-011-0172-2. PMID 22198808. S2CID 7329783.
Bostanci A (February 2005). "Wildlife biology. A devil of a disease". Science. 307 (5712): 1035. doi:10.1126/science.307.5712.1035. PMID 15718445. S2CID 54100368. The tumors [of Devil facial tumor disease] have been characterized as a neuroendocrine cancer
Langley K (September 1994). "The neuroendocrine concept today". Annals of the New York Academy of Sciences. 733 (1): 1–17. Bibcode:1994NYASA.733....1L. doi:10.1111/j.1749-6632.1994.tb17251.x. PMID 7978856. S2CID 33139633.
Ferolla P, Faggiano A, Mansueto G, Avenia N, Cantelmi MG, Giovenali P, et al. (March 2008). "The biological characterization of neuroendocrine tumors: the role of neuroendocrine markers". Journal of Endocrinological Investigation. 31 (3): 277–286. doi:10.1007/bf03345602. PMID 18401212. S2CID 25108086.
Oberg K (July 2005). "Neuroendocrine tumors of the gastrointestinal tract: recent advances in molecular genetics, diagnosis, and treatment". Current Opinion in Oncology. 17 (4): 386–391. doi:10.1097/01.cco.0000167739.56948.a9. PMID 15933475. S2CID 208286399.
van Essen M, Sundin A, Krenning EP, Kwekkeboom DJ (February 2014). "Neuroendocrine tumours: the role of imaging for diagnosis and therapy". Nature Reviews. Endocrinology. 10 (2): 102–114. doi:10.1038/nrendo.2013.246. PMID 24322649. S2CID 40129404.
Hofman MS, Kong G, Neels OC, Eu P, Hong E, Hicks RJ (February 2012). "High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours". Journal of Medical Imaging and Radiation Oncology. 56 (1): 40–47. doi:10.1111/j.1754-9485.2011.02327.x. PMID 22339744. S2CID 21843609.
Scott AT, Howe JR (August 2018). "Management of Small Bowel Neuroendocrine Tumors". Journal of Oncology Practice. 14 (8): 471–482. doi:10.1200/JOP.18.00135. PMC 6091496. PMID 30096273.
Hofman MS, Hicks RJ (July 2012). "Changing paradigms with molecular imaging of neuroendocrine tumors". Discovery Medicine. 14 (74): 71–81. PMID 22846204. Retrieved November 8, 2015.
Hofland J, Kaltsas G, de Herder WW (April 2020). "Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms". Endocrine Reviews. 41 (2): 371–403. doi:10.1210/endrev/bnz004. PMC 7080342. PMID 31555796.
Nilica B, Waitz D, Stevanovic V, Uprimny C, Kendler D, Buxbaum S, et al. (August 2016). "Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle". European Journal of Nuclear Medicine and Molecular Imaging. 43 (9): 1585–1592. doi:10.1007/s00259-016-3328-2. PMC 4932132. PMID 26922350.
Van Buren G, Rashid A, Yang AD, Abdalla EK, Gray MJ, Liu W, et al. (August 2007). "The development and characterization of a human midgut carcinoid cell line". Clinical Cancer Research. 13 (16): 4704–4712. doi:10.1158/1078-0432.CCR-06-2723. PMID 17699847.
Berretta M, Cappellani A, Di Vita M, Berretta S, Nasti G, Bearz A, et al. (January 2010). "Biomarkers in neuroendocrine tumors". Frontiers in Bioscience. 2 (1): 332–342. doi:10.2741/s68. PMID 20036951.
Mukhopadhyay S, Dermawan JK, Lanigan CP, Farver CF (January 2019). "Insulinoma-associated protein 1 (INSM1) is a sensitive and highly specific marker of neuroendocrine differentiation in primary lung neoplasms: an immunohistochemical study of 345 cases, including 292 whole-tissue sections". Modern Pathology. 32 (1): 100–109. doi:10.1038/s41379-018-0122-7. PMID 30154579. S2CID 52110673.
Warner RR (May 2005). "Enteroendocrine tumors other than carcinoid: a review of clinically significant advances". Gastroenterology. 128 (6): 1668–1684. doi:10.1053/j.gastro.2005.03.078. PMID 15887158.
Öberg K (1998). "Carcinoid Tumors: Current Concepts in Diagnosis and Treatment". The Oncologist. 3 (5): 339–345. doi:10.1634/theoncologist.3-5-339. PMID 10388123.
Oberg K, Akerström G, Rindi G, Jelic S (May 2010). "Neuroendocrine gastroenteropancreatic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up". Annals of Oncology. 21 (Suppl 5): v223 – v227. doi:10.1093/annonc/mdq192. PMID 20555086.
Clark OH, Benson AB, Berlin JD, Choti MA, Doherty GM, Engstrom PF, et al. (July 2009). "NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors". Journal of the National Comprehensive Cancer Network. 7 (7): 712–747. doi:10.6004/jnccn.2009.0050. PMID 19635226.
Rinke A, Auernhammer CJ, Bodei L, Kidd M, Krug S, Lawlor R, et al. (September 2021). "Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine?". Gut. 70 (9): 1768–1781. doi:10.1136/gutjnl-2020-321300. PMID 33692095. S2CID 232172557.
Oberg K, Kvols L, Caplin M, Delle Fave G, de Herder W, Rindi G, et al. (June 2004). "Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system". Annals of Oncology. 15 (6): 966–973. doi:10.1093/annonc/mdh216. PMID 15151956.
Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. (October 2009). "Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group". Journal of Clinical Oncology. 27 (28): 4656–4663. doi:10.1200/JCO.2009.22.8510. PMID 19704057.
Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, et al. (July 2014). "Lanreotide in metastatic enteropancreatic neuroendocrine tumors". The New England Journal of Medicine. 371 (3): 224–233. doi:10.1056/NEJMoa1316158. PMID 25014687.
Chan JA, Kulke MH (May 2009). "Progress in the treatment of neuroendocrine tumors". Current Oncology Reports. 11 (3): 193–199. doi:10.1007/s11912-009-0028-0. PMC 4029419. PMID 19336011.
Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. (January 2017). "Phase 3 Trial of ¹⁷⁷Lu-Dotatate for Midgut Neuroendocrine Tumors". The New England Journal of Medicine. 376 (2): 125–135. doi:10.1056/nejmoa1607427. hdl:2445/125256. PMC 5895095. PMID 28076709.
Kratochwil C, Giesel FL, Bruchertseifer F, Mier W, Apostolidis C, Boll R, et al. (November 2014). "²¹³Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience". European Journal of Nuclear Medicine and Molecular Imaging. 41 (11): 2106–2119. doi:10.1007/s00259-014-2857-9. PMC 4525192. PMID 25070685.
Kashyap R, Hofman MS, Michael M, Kong G, Akhurst T, Eu P, et al. (February 2015). "Favourable outcomes of (177)Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours". European Journal of Nuclear Medicine and Molecular Imaging. 42 (2): 176–185. doi:10.1007/s00259-014-2906-4. PMID 25209134. S2CID 20740102.
Hofman MS, Michael M, Kashyap R, Hicks RJ (June 2015). "Modifying the Poor Prognosis Associated with 18F-FDG-Avid NET with Peptide Receptor Chemo-Radionuclide Therapy (PRCRT)". Journal of Nuclear Medicine. 56 (6): 968–969. doi:10.2967/jnumed.115.154500. PMID 25814516. S2CID 207407820.
Welsh JS, Kennedy AS, Thomadsen B (2006). "Selective Internal Radiation Therapy (SIRT) for liver metastases secondary to colorectal adenocarcinoma". International Journal of Radiation Oncology, Biology, Physics. 66 (2 Suppl): S62 – S73. doi:10.1016/j.ijrobp.2005.09.011. PMID 16979443.
Van De Wiele C, Defreyne L, Peeters M, Lambert B (June 2009). "Yttrium-90 labelled resin microspheres for treatment of primary and secondary malignant liver tumors". The Quarterly Journal of Nuclear Medicine and Molecular Imaging. 53 (3): 317–324. PMID 19521311.
Salem R, Thurston KG, Carr BI, Goin JE, Geschwind JF (September 2002). "Yttrium-90 microspheres: radiation therapy for unresectable liver cancer". Journal of Vascular and Interventional Radiology. 13 (9 Pt 2): S223 – S229. doi:10.1016/S1051-0443(07)61790-4. PMID 12354840.
Detjen K, Hammerich L, Özdirik B, Demir M, Wiedenmann B, Tacke F, et al. (2020-07-02). "Models of Gastroenteropancreatic Neuroendocrine Neoplasms: Current Status and Future Directions". Neuroendocrinology. 111 (3): 217–236. doi:10.1159/000509864. PMID 32615560.
April-Monn SL, Kirchner P, Detjen K, Bräutigam K, Trippel MA, Grob T, et al. (March 2024). "Patient derived tumoroids of high grade neuroendocrine neoplasms for more personalized therapies". npj Precision Oncology. 8 (1): 59. doi:10.1038/s41698-024-00549-2. PMC 10907580. PMID 38429350.
April-Monn SL, Wiedmer T, Skowronska M, Maire R, Schiavo Lena M, Trippel M, et al. (2020-04-03). "Three-Dimensional Primary Cell Culture: A Novel Preclinical Model for Pancreatic Neuroendocrine Tumors". Neuroendocrinology. 111 (3): 273–287. doi:10.1159/000507669. hdl:11392/2447420. PMID 32241015. S2CID 214768622.
Oberg K, Castellano D (March 2011). "Current knowledge on diagnosis and staging of neuroendocrine tumors". Cancer and Metastasis Reviews. 30 (Suppl 1): 3–7. doi:10.1007/s10555-011-9292-1. PMID 21311954. S2CID 29720754.
Kimura W, Kuroda A, Morioka Y (July 1991). "Clinical pathology of endocrine tumors of the pancreas. Analysis of autopsy cases". Digestive Diseases and Sciences. 36 (7): 933–942. doi:10.1007/BF01297144. PMID 2070707. S2CID 20567425.
Modlin IM, Shapiro MD, Kidd M (December 2004). "Siegfried Oberndorfer: origins and perspectives of carcinoid tumors". Human Pathology. 35 (12): 1440–1451. doi:10.1016/j.humpath.2004.09.018. PMID 15619202.

ncbi.nlm.nih.gov

Ramage JK, Davies AH, Ardill J, Bax N, Caplin M, Grossman A, et al. (June 2005). "Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours". Gut. 54. 54 (Suppl 4): iv1 – i16. doi:10.1136/gut.2004.053314. PMC 1867801. PMID 15888809.
Scalettar BA, Jacobs C, Fulwiler A, Prahl L, Simon A, Hilken L, Lochner JE (September 2012). "Hindered submicron mobility and long-term storage of presynaptic dense-core granules revealed by single-particle tracking". Developmental Neurobiology. 72 (9): 1181–1195. doi:10.1002/dneu.20984. PMC 3512567. PMID 21976424.
Oronsky B, Ma PC, Morgensztern D, Carter CA (December 2017). "Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas". Neoplasia. 19 (12): 991–1002. doi:10.1016/j.neo.2017.09.002. PMC 5678742. PMID 29091800.
Tan EH, Tan CH (January 2011). "Imaging of gastroenteropancreatic neuroendocrine tumors". World Journal of Clinical Oncology. 2 (1): 28–43. doi:10.5306/wjco.v2.i1.28. PMC 3095463. PMID 21603312.
Massironi S, Sciola V, Peracchi M, Ciafardini C, Spampatti MP, Conte D (September 2008). "Neuroendocrine tumors of the gastro-entero-pancreatic system". World Journal of Gastroenterology. 14 (35): 5377–5384. doi:10.3748/wjg.14.5377. PMC 2744160. PMID 18803349.
Metz DC, Jensen RT (November 2008). "Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors". Gastroenterology. 135 (5): 1469–1492. doi:10.1053/j.gastro.2008.05.047. PMC 2612755. PMID 18703061.
Griniatsos J, Michail O (April 2010). "Appendiceal neuroendocrine tumors: Recent insights and clinical implications". World Journal of Gastrointestinal Oncology. 2 (4): 192–196. doi:10.4251/wjgo.v2.i4.192. PMC 2999180. PMID 21160597.
Ni SJ, Sheng WQ, Du X (April 2010). "Pathologic research update of colorectal neuroendocrine tumors". World Journal of Gastroenterology. 16 (14): 1713–1719. doi:10.3748/wjg.v16.i14.1713. PMC 2852818. PMID 20380002.
Konishi T, Watanabe T, Nagawa H, Oya M, Ueno M, Kuroyanagi H, et al. (May 2010). "Treatment of colorectal carcinoids: A new paradigm". World Journal of Gastrointestinal Surgery. 2 (5): 153–156. doi:10.4240/wjgs.v2.i5.153. PMC 2999232. PMID 21160865.
Nikfarjam M, Muralidharan V, Christophi C (2004). "Primary hepatic carcinoid tumours". HPB. 6 (1): 13–17. doi:10.1080/13651820310017228. PMC 2020649. PMID 18333038.
Jensen RT, Berna MJ, Bingham DB, Norton JA (October 2008). "Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies". Cancer. 113 (7 Suppl): 1807–1843. doi:10.1002/cncr.23648. PMC 2574000. PMID 18798544.
Lodish MB, Stratakis CA (June 2010). "Endocrine tumours in neurofibromatosis type 1, tuberous sclerosis and related syndromes". Best Practice & Research. Clinical Endocrinology & Metabolism. 24 (3): 439–449. doi:10.1016/j.beem.2010.02.002. PMC 2939061. PMID 20833335.
Basturk O, Yang Z, Tang LH, Hruban RH, Adsay V, McCall CM, et al. (May 2015). "The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms". The American Journal of Surgical Pathology. 39 (5): 683–690. doi:10.1097/PAS.0000000000000408. PMC 4398606. PMID 25723112.
PDQ Adult Treatment Editorial Board (August 2022). "Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®): Health Professional Version". PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute. PMID 26389309.
Scott AT, Howe JR (August 2018). "Management of Small Bowel Neuroendocrine Tumors". Journal of Oncology Practice. 14 (8): 471–482. doi:10.1200/JOP.18.00135. PMC 6091496. PMID 30096273.
Hofland J, Kaltsas G, de Herder WW (April 2020). "Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms". Endocrine Reviews. 41 (2): 371–403. doi:10.1210/endrev/bnz004. PMC 7080342. PMID 31555796.
Nilica B, Waitz D, Stevanovic V, Uprimny C, Kendler D, Buxbaum S, et al. (August 2016). "Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle". European Journal of Nuclear Medicine and Molecular Imaging. 43 (9): 1585–1592. doi:10.1007/s00259-016-3328-2. PMC 4932132. PMID 26922350.
Chan JA, Kulke MH (May 2009). "Progress in the treatment of neuroendocrine tumors". Current Oncology Reports. 11 (3): 193–199. doi:10.1007/s11912-009-0028-0. PMC 4029419. PMID 19336011.
Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. (January 2017). "Phase 3 Trial of ¹⁷⁷Lu-Dotatate for Midgut Neuroendocrine Tumors". The New England Journal of Medicine. 376 (2): 125–135. doi:10.1056/nejmoa1607427. hdl:2445/125256. PMC 5895095. PMID 28076709.
Kratochwil C, Giesel FL, Bruchertseifer F, Mier W, Apostolidis C, Boll R, et al. (November 2014). "²¹³Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience". European Journal of Nuclear Medicine and Molecular Imaging. 41 (11): 2106–2119. doi:10.1007/s00259-014-2857-9. PMC 4525192. PMID 25070685.
April-Monn SL, Kirchner P, Detjen K, Bräutigam K, Trippel MA, Grob T, et al. (March 2024). "Patient derived tumoroids of high grade neuroendocrine neoplasms for more personalized therapies". npj Precision Oncology. 8 (1): 59. doi:10.1038/s41698-024-00549-2. PMC 10907580. PMID 38429350.

omim.org

"Carney Complex, type 1; CNC1". OMIM - Online Mendelian Inheritance in Man. OMIM 160980.
"Carney Complex, type 2; CNC2". OMIM - Online Mendelian Inheritance in Man. OMIM 605244.

semanticscholar.org

api.semanticscholar.org

Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S (August 2010). "The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems". Pancreas. 39 (6): 707–712. doi:10.1097/MPA.0b013e3181ec124e. PMID 20664470. S2CID 3735444.
van Eeden S, Offerhaus GJ, Hart AA, Boerrigter L, Nederlof PM, Porter E, van Velthuysen ML (December 2007). "Goblet cell carcinoid of the appendix: a specific type of carcinoma". Histopathology. 51 (6): 763–773. doi:10.1111/j.1365-2559.2007.02883.x. PMID 18042066. S2CID 20185589.
Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens LA, et al. (March 2022). "Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms". Endocrine Pathology. 33 (1): 115–154. doi:10.1007/s12022-022-09708-2. PMID 35294740. S2CID 247455289.
Liu Y, Sturgis CD, Grzybicki DM, Jasnosz KM, Olson PR, Tong M, et al. (September 2001). "Microtubule-associated protein-2: a new sensitive and specific marker for pulmonary carcinoid tumor and small cell carcinoma". Modern Pathology. 14 (9): 880–885. doi:10.1038/modpathol.3880406. PMID 11557784. S2CID 24740130.
Gustafsson BI, Kidd M, Chan A, Malfertheiner MV, Modlin IM (July 2008). "Bronchopulmonary neuroendocrine tumors". Cancer. 113 (1): 5–21. doi:10.1002/cncr.23542. PMID 18473355. S2CID 22143641.
Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, et al. (January 2008). "Gastroenteropancreatic neuroendocrine tumours". The Lancet. Oncology. 9 (1): 61–72. doi:10.1016/S1470-2045(07)70410-2. PMID 18177818. S2CID 46127116.
Usmani S, Orevi M, Stefanelli A, Zaniboni A, Gofrit ON, Bnà C, et al. (June 2019). "Neuroendocrine differentiation in castration resistant prostate cancer. Nuclear medicine radiopharmaceuticals and imaging techniques: A narrative review". Critical Reviews in Oncology/Hematology. 138: 29–37. doi:10.1016/j.critrevonc.2019.03.005. PMID 31092382. S2CID 131934021.
Davies AH, Beltran H, Zoubeidi A (May 2018). "Cellular plasticity and the neuroendocrine phenotype in prostate cancer". Nature Reviews. Urology. 15 (5): 271–286. doi:10.1038/nrurol.2018.22. PMID 29460922. S2CID 4732323.
Kimura W, Kuroda A, Morioka Y (July 1991). "Clinical pathology of endocrine tumors of the pancreas. Analysis of autopsy cases". Digestive Diseases and Sciences. 36 (7): 933–942. doi:10.1007/BF01297144. PMID 2070707. S2CID 20567425. "[In] 800 autopsy cases, ... incidence of tumor was 10% (6/60) in individuals having histiological studies of all sections of the pancreas"
Burns WR, Edil BH (March 2012). "Neuroendocrine pancreatic tumors: guidelines for management and update". Current Treatment Options in Oncology. 13 (1): 24–34. doi:10.1007/s11864-011-0172-2. PMID 22198808. S2CID 7329783.
Bostanci A (February 2005). "Wildlife biology. A devil of a disease". Science. 307 (5712): 1035. doi:10.1126/science.307.5712.1035. PMID 15718445. S2CID 54100368. The tumors [of Devil facial tumor disease] have been characterized as a neuroendocrine cancer
Langley K (September 1994). "The neuroendocrine concept today". Annals of the New York Academy of Sciences. 733 (1): 1–17. Bibcode:1994NYASA.733....1L. doi:10.1111/j.1749-6632.1994.tb17251.x. PMID 7978856. S2CID 33139633.
Ferolla P, Faggiano A, Mansueto G, Avenia N, Cantelmi MG, Giovenali P, et al. (March 2008). "The biological characterization of neuroendocrine tumors: the role of neuroendocrine markers". Journal of Endocrinological Investigation. 31 (3): 277–286. doi:10.1007/bf03345602. PMID 18401212. S2CID 25108086.
Oberg K (July 2005). "Neuroendocrine tumors of the gastrointestinal tract: recent advances in molecular genetics, diagnosis, and treatment". Current Opinion in Oncology. 17 (4): 386–391. doi:10.1097/01.cco.0000167739.56948.a9. PMID 15933475. S2CID 208286399.
van Essen M, Sundin A, Krenning EP, Kwekkeboom DJ (February 2014). "Neuroendocrine tumours: the role of imaging for diagnosis and therapy". Nature Reviews. Endocrinology. 10 (2): 102–114. doi:10.1038/nrendo.2013.246. PMID 24322649. S2CID 40129404.
Hofman MS, Kong G, Neels OC, Eu P, Hong E, Hicks RJ (February 2012). "High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours". Journal of Medical Imaging and Radiation Oncology. 56 (1): 40–47. doi:10.1111/j.1754-9485.2011.02327.x. PMID 22339744. S2CID 21843609.
Mukhopadhyay S, Dermawan JK, Lanigan CP, Farver CF (January 2019). "Insulinoma-associated protein 1 (INSM1) is a sensitive and highly specific marker of neuroendocrine differentiation in primary lung neoplasms: an immunohistochemical study of 345 cases, including 292 whole-tissue sections". Modern Pathology. 32 (1): 100–109. doi:10.1038/s41379-018-0122-7. PMID 30154579. S2CID 52110673.
Rinke A, Auernhammer CJ, Bodei L, Kidd M, Krug S, Lawlor R, et al. (September 2021). "Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine?". Gut. 70 (9): 1768–1781. doi:10.1136/gutjnl-2020-321300. PMID 33692095. S2CID 232172557.
Kashyap R, Hofman MS, Michael M, Kong G, Akhurst T, Eu P, et al. (February 2015). "Favourable outcomes of (177)Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours". European Journal of Nuclear Medicine and Molecular Imaging. 42 (2): 176–185. doi:10.1007/s00259-014-2906-4. PMID 25209134. S2CID 20740102.
Hofman MS, Michael M, Kashyap R, Hicks RJ (June 2015). "Modifying the Poor Prognosis Associated with 18F-FDG-Avid NET with Peptide Receptor Chemo-Radionuclide Therapy (PRCRT)". Journal of Nuclear Medicine. 56 (6): 968–969. doi:10.2967/jnumed.115.154500. PMID 25814516. S2CID 207407820.
April-Monn SL, Wiedmer T, Skowronska M, Maire R, Schiavo Lena M, Trippel M, et al. (2020-04-03). "Three-Dimensional Primary Cell Culture: A Novel Preclinical Model for Pancreatic Neuroendocrine Tumors". Neuroendocrinology. 111 (3): 273–287. doi:10.1159/000507669. hdl:11392/2447420. PMID 32241015. S2CID 214768622.
Oberg K, Castellano D (March 2011). "Current knowledge on diagnosis and staging of neuroendocrine tumors". Cancer and Metastasis Reviews. 30 (Suppl 1): 3–7. doi:10.1007/s10555-011-9292-1. PMID 21311954. S2CID 29720754.
Kimura W, Kuroda A, Morioka Y (July 1991). "Clinical pathology of endocrine tumors of the pancreas. Analysis of autopsy cases". Digestive Diseases and Sciences. 36 (7): 933–942. doi:10.1007/BF01297144. PMID 2070707. S2CID 20567425.

telegraph.co.uk

Masters A (2016-07-02). "Can crowdfunding really cure cancer? Alexander Masters investigates a pioneering new project". The Telegraph. Archived from the original on 2016-07-03. Retrieved 2016-07-03.

time.com

Walsh B (January 1, 2010). "Decoding the Tasmanian Devil's Deadly Cancer". Time. Archived from the original on January 8, 2010.

uptodate.com

AJCC, 8th edition: Klimstra DS, Yang Z (29 October 2019). "Pathology, classification, and grading of neuroendocrine neoplasms arising in the digestive system". UpToDate.

web.archive.org

Pommier R (October 2003). The role of surgery and chemoembolization in the management of carcinoid. California Carcinoid Fighters Conference. Archived from the original on 2015-09-15.
"Carcinoid Tumor Overview". Health Communities. Archived from the original on 2012-03-03.
Kvols LK (2002). "Carcinoid Tumors and the Carcinoid Syndrome: What's New in the Therapeutic Pipeline". Carcinoid Symposium 2002. The Carcinoid Cancer Foundation. Archived from the original on 2015-01-05.
Benson AB, Myerson RJ, Sasson AR (March 2011). "Pancreatic, neuroendocrine GI, and adrenal cancers.". Cancer Management: A Multidisciplinary Approach (13th ed.). UBM Medica. ISBN 978-0-615-41824-7. Archived from the original on 2011-05-15., cancernetwork.com; accessed November 8, 2015.
Kinver M (January 1, 2010). "Tasmanian devil facial cancer origins 'identified'". BBC. Archived from the original on January 2, 2010.
Walsh B (January 1, 2010). "Decoding the Tasmanian Devil's Deadly Cancer". Time. Archived from the original on January 8, 2010.
McMorran J, Crowther DC, McMorran S, Prince C, YoungMin S, Pleat J, Wacogne I. "investigations – General Practice Notebook". www.gpnotebook.co.uk. Archived from the original on 24 February 2017. Retrieved 23 February 2017.
Tebbi CK, Windle ML, Cripe TP, Sakamoto KM (1 April 2014). Coppes MJ (ed.). "Carcinoid Tumor". Medscape.com. WebMD LLC. Archived from the original on 15 December 2014. Retrieved 3 September 2014.
"Islet Cell Tumors (Endocrine Pancreas)". National Cancer Institute. Archived from the original on 2011-06-07.
"Gastrointestinal Carcinoid Tumors Treatment". National Cancer Institute. Archived from the original on 2011-06-27.
"Merkel cell tumors". National Cancer Institute. 21 February 2006. Archived from the original on 2011-06-07.
"Pheochromocytoma and Paraganglioma". National Cancer Institute. Archived from the original on 2011-06-07.
Fong T, Schoenfield LJ. "Arterial Chemotherapy Infusion of the Liver (and) Chemoembolization of the Liver (TACE)". medicinenet.com. Archived from the original on 2014-12-24. Retrieved 8 November 2015.
Masters A (2014-10-14). "A plutocratic proposal". Mosaic. The Wellcome Trust. Archived from the original on 2016-05-29. Retrieved 2016-07-03.
"iCancer web site". icancer.org.uk. Archived from the original on 2016-07-14. Retrieved 2016-07-03.
Masters A (2016-07-02). "Can crowdfunding really cure cancer? Alexander Masters investigates a pioneering new project". The Telegraph. Archived from the original on 2016-07-03. Retrieved 2016-07-03.